Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone furoate/vilanterol - GSK/Innoviva

Drug Profile

Fluticasone furoate/vilanterol - GSK/Innoviva

Alternative Names: '444/'698; 444/698; Breo Ellipta; FF/GW642444; FF/VI; Fluticasone furoate/GW642444; Fluticasone furoate/vilanterol trifenatate; Fluticasone-furoate/vilanterol; GSK-2285997; GW642444/GW685698; GW642444M/GW685698X; GW685698/GW642444; GW685698X/GW642444M; Relovair; Relvar Ellipta; RELVAR®/BREO® ELLIPTA®; Revinty Ellipta

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GSK; Innoviva
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorobenzenes; Ethers; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 19 May 2023 Efficacy and adverse events data from a phase III trial in Asthma presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
  • 21 Mar 2022 GlaxoSmithKline completes a phase III trial in Asthma (In children, In adolescents) in the US, Argentina, China, Canada, Japan, Mexico, Romania, Russia, South Africa, Poland, Lithuania, Hungary, Bulgaria, Italy, Germany, and Spain (Inhalation) in March 2022 (EudraCT2016-004086-87) (NCT03248128)
  • 14 May 2021 Interim efficacy data from a phase III CAPTAIN trial in Asthma presented 117th International Conference of the American Thoracic Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top